ArticleJournal of pharmaceutical policy and practice2021
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits.
Darren K McGuire et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.